Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Pfizer
Scientific Title
A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor